HCM
NVIV

Highbridge Capital Management’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Highbridge Capital Management’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed -$74K – 1848
2016
Q2 		$74K Buy
+1
New +$118K ﹤0.01% 1323

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Highbridge Capital Management's NVIV Position: Q3 2016 in Review

Highbridge Capital Management sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q3 2016, closing a stake of 1 share — an estimated $74K sold.

Highbridge Capital Management first reported a position in NVIV in Q2 2016 and held it in 1 quarter. The position peaked at $74K in Q2 2016. 45 funds tracked by Wall St. Rank hold NVIV as of Q3 2016.

  • Highbridge Capital Management reported no remaining InVivo Therapeutics Holdings Corp position as of Q3 2016 after selling out during the quarter.
  • Highbridge Capital Management sold 1 InVivo Therapeutics Holdings Corp share in Q3 2016, an estimated $74K.
  • Highbridge Capital Management first reported a position in InVivo Therapeutics Holdings Corp in Q2 2016 and held it in 1 quarter.
  • Highbridge Capital Management's InVivo Therapeutics Holdings Corp position peaked at $74K in Q2 2016.
  • 45 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q3 2016.

Based on Highbridge Capital Management's 13F filing for Q3 2016, filed 14 Nov 2016.